PUBLIC CONTRACT · 2021
211000575 - Ano 2021 - SPMS 2019/40
- Contract value
- €435,480.00
- Signed on
- 6 May 2021
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 7646721PUBLISHED SUBJECT
211000575 - AQ.BICTEGRAVIR 50 MG + EMTRICITABINA 200 MG + TENOFOVIR ALAFENAMIDA 25 MG COMP
Parties involved
- Place of performance
- Portugal, Lisboa, Lisboa
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- Gilead Sciences, Lda. · Tax ID 503604704
Values and timeline
- Contract price
- €435,480.00
- Procedure base price
- €435,480.00
- Total effective price
- Not reported on Portal BASE
- Publication date
- 6 May 2021
- Award date
- 29 April 2021
- Signing date
- 6 May 2021
- Performance period
- 239 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Melhor relação qualidade – preço
- CPV code
- 33651000-8 - Anti-infecciosos gerais de uso sistémico
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- CP 2019/40 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5255561
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.